Zimmer Biomet Holdings (ZBH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.07
- Estimate
- $2.01
- Surprise
- +3.0%
- Revenue (period 2026-06-30)
- $2.18B
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
Zimmer Biomet Holdings (ZBH) beat the $2.01 estimate with diluted EPS of $2.07 — a modest 3.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZBH Hold at 5.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +3.0% surprise compares with a +4.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: single-source materials and components
- Analyst target reached - limited upside remaining
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $98.32
- Price target
- $100.80
- Stop
- $93.27
- Upside to target
- +2.5%
The stock trades at 24.1× trailing but 10.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ZBH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $18.87B
- P/E (fwd)
- 10.9
- P/E (ttm)
- 24.1
- 52-week range
- $79.12–$106.88
- Off 52-week high
- 8.0%
- RSI (14)
- 50
- Volume vs avg
- 0.08×
- Score today
- 5.9/10